News and blogs
334 results found.
My father would have never believed I'd be running half marathon!
Bradley was a financial advisor at St James’s Place Wealth Management who supported our charity for many years. Bradley lived with MPN (myeloproliferative neoplasms) and was diagnosed with acute myeloid leukaemia in March 2022. Despite beginning chemotherapy immediately, Bradley sadly passed away after just two weeks of treatment. Bradley's daughter, Lara, writes about how she's carrying on her father's fundraising mission.
How thinking differently about Pride is helping us do more to beat blood cancer
When we think about Pride today, often the first things that spring to mind are colourful marches, rainbow flags… a celebration of diversity. But is that what Pride should be about?
Targeting tumour stroma could improve immunotherapy response in those with lymphoma
Researchers at King’s College London have shown how specific cells known as ‘fibroblast cells’ in lymphoma tumours suppress the body’s immune cells and immunotherapy treatment. The Blood Cancer UK funded work highlights the potential of harnessing these fibroblasts to help rejuvenate the body’s immune cells (T-cells) using novel immunotherapy drugs. The scientific paper, the Journal of Clinical Investigation published the results.
Read Ed's story of being diagnosed with CLL
Ed shares his story of how our Clinical Trials Support Service helped support him through his diagnosis of CLL
Being part of the FLAIR trial has been an amazing opportunity
In this blog, James, who is living with chronic lymphocytic leukaemia, tells us about his journey with blood cancer, and discusses what research means to him.
Blood cancer drug trial results in better outcomes than those on best-available existing medication
A drug, ruxolitinib, has been found to be better at treating the blood cancer - polycythaemia vera (PV) than the best currently available treatment. Researchers looked at how well the drug worked in those who don’t respond well to the first line of treatment in a randomized phase-II clinical trial. Blood Cancer UK funded the work through the Trials Acceleration Programme.
Three years later: should high risk people still be shielding from Covid?
Three years on from the start of the Covid pandemic, we look at what information there is for people with blood cancer to decide how to balance risk from the virus with wanting to get on with living their lives as normally as possible.
Our letter to the UK Health Security Agency representing immunocompromised people
With a coalition of 11 other charities and organisations representing immunocompromised people, we've written to UK Health Security Agency chief, Dame Jenny Harries, to ask about the pause and review of the ONS Covid-19 Infection Survey and urged her to reconsider. Here is the letter in full:
Research suggests drug improves stem cell transplants for those with multiple myeloma
Researchers in the US have shed light on a way to carry out stem cell transplants in people with multiple myeloma more efficiently, using a drug called motixafortide. The scientific journal, Nature Medicine, published the findings, today (Monday 17 April).
Why taking away that worry of the cancer returning would be life changing…
We’ve recently funded 16 new research projects, but we couldn’t fund research without you, our community who so generously donate to blood cancer research. In this blog we hear from Carole who talks about what this latest research means to her.
We’re delighted to be funding 16 new research projects
We are delighted to announce funding for 16 new research projects across the UK, worth over £4million. The projects span all types of blood cancer and bring our total funding portfolio to 74 different research projects across 23 different institutions in the UK.
I want others to listen and know they're not alone
The new Blood Cancer Heart to Heart podcast is for everyone who has a friend or family member with blood cancer
Tom Youngs speaks publicly about his late wife, Tiff, as Will Findlay takes on new challenge
Former British and Irish Lions player, ex-England hooker and Leicester Tigers club captain Tom Youngs has spoken publicly for the first time about his wife Tiffany, sadly passed away to blood cancer in 2022.
Evusheld decision leaves members of blood cancer community disappointed
Today (16 February) NICE has deemed that there’s not enough evidence to say Evusheld is clinically effective against COVID-19 in the UK. NICE also said it is developing a new review process to update recommendations on the cost-effectiveness of COVID-19 treatments, so they can be made available more quickly if they show promise against new variants and are found to be cost-effective.
My priorities as chief executive of Blood Cancer UK
Helen gives her thoughts on her new role as Chief Executive of Blood Cancer UK.
World Cancer Day: Over 50% of UK adults can’t name a single symptom
This Saturday 4th Feb is #WorldCancerDay and we want you to help us shine a light on blood cancer. Why? Because despite being the fifth most common cancer, over 50% of UK adults can’t name a single symptom. Here's how you can get involved...
Blood cancer and travel: your guide
Tips for going on holiday when you have blood cancer, from symptoms and side effects, to packing medication and avoiding infections.
Tips on keeping safe in the sun
Clinical Nurse Specialist Jodie Nightingill gives her tips for enjoying the sunshine safely if you have blood cancer.
Blood Cancer UK disappointed by the Government’s ‘Major Conditions Strategy’
The Government’s Department of Health and Social Care announced a new UK wide ‘Major Conditions Strategy’, which they say will try to alleviate pressure on the health system. In 2022, the UK government had promised a 10-year cancer plan, however this new Major Conditions Strategy will now supersede this.
Blood cancer therapy to become routinely available for third line use on NHS
Today (Thursday 26 January), a review from National Institute for Health and Care Excellence (NICE) has deemed the blood cancer CAR-T therapy, axicabtagene ciloleucel (Yescarta), cost effective for routine use on the NHS in England.
